REVIVA PHARMACEUTICALS HOLDINGS, INC.
RVPH evidence brief
What we can confirm
- Market Cap:
- $6.3M
What it means
What to watch
Prepared research question
What matters most for RVPH—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · RVPH
Reviva Pharmaceuticals Holdings, Inc. (RVPH) is a late-stage biopharmaceutical company focused on developing brilaroxazine for schizophrenia and other CNS disorders, with no approved products and a single advanced clinical candidate.
Key risk: Single-product dependency
Market Cap
$6.3M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 1 clinical trial for REVIVA PHARMACEUTICALS HOLDINGS, INC..
Reviva Pharmaceuticals Holdings, Inc. (RVPH) is a late-stage biopharmaceutical company focused on developing brilaroxazine for schizophrenia and other CNS disorders, with no approved products and a single advanced clinical candidate.
- Cash & equivalents of $19.9M as of 2026-06-30 [sec].
- Net loss of $2.4M for the period ending 2026-06-30 [sec].
- Shareholders' equity of $15.2M as of 2026-06-30 [sec].
- Brilaroxazine is the only advanced product candidate; RP1208 is in pre-clinical phase [sec · filed 2026-04-15].
- FDA feedback on use of new brilaroxazine formulation in RECOVER-2 trial and NDA expected Q4 2026 [news · published 2026-08-12].
What works
- Company has filed a U.S. composition of matter patent application seeking to extend brilaroxazine exclusivity through 2046, potentially strengthening lifecycle management [news · published 2026-08-12].
- European patent granted covering brilaroxazine for pulmonary fibrosis, adding to global IP protection [news · published 2025-11-13].
- Published vocal biomarker data from RECOVER Phase 3 trial supports brilaroxazine's effect on negative symptoms in schizophrenia [news · published 2026-01-08].
What to weigh
- Company has no approved products and may never develop marketable drug products; business depends entirely on brilaroxazine [sec · filed 2026-04-15].
- Existing cash of $19.9M as of 2026-06-30 is not sufficient to complete development; significant additional capital is needed [sec_mda · as of 2026-03-30].
- Company expects to continue incurring significant operating losses for the foreseeable future [sec_mda · as of 2026-03-30].
- FDA recommended a second Phase 3 study (RECOVER-2) for brilaroxazine, delaying potential approval [news · published 2026-04-01].
From the filings
Quoted directly from source documents.
FDA feedback on new brilaroxazine formulation and NDA expected Q4 2026.
“FDA feedback on use of new brilaroxazine formulation in the RECOVER-2 trial and NDA expected Q4 2026”
News · August 12, 2026
Cash and cash equivalents of approximately $14.4 million as of December 31, 2025.
“As of December 31, 2025, we had cash and cash equivalents of approximately $14.4 million.”
SEC MD&A · March 30, 2026
Company expects to continue incurring significant operating losses.
“We expect to continue to incur significant expenses and operating losses for the foreseeable future”
SEC MD&A · March 30, 2026
Risks & what to watch (4)›
Key risks
- Single-product dependency — Business depends entirely on brilaroxazine; failure to gain approval would harm the company [sec · filed 2026-04-15].
- Insufficient cash runway — Cash of $19.9M as of 2026-06-30 is not enough to complete development; additional capital needed [sec_mda · as of 2026-03-30].
- Regulatory delay risk — FDA required a second Phase 3 trial (RECOVER-2), pushing potential NDA submission to at least Q4 2026 [news · published 2026-08-12].
- No profitability in sight — Company has never been profitable and expects continued operating losses [sec_mda · as of 2026-03-30].
What to watch
- FDA feedback on new brilaroxazine formulation and NDA timing expected Q4 2026 [news · published 2026-08-12].
- Initiation of patient enrollment in RECOVER-2 registrational Phase 3 trial expected in 1H 2027 [news · published 2026-08-12].
- Company's ability to raise additional capital to fund operations and development [sec_mda · as of 2026-03-30].
- Outcome of composition of matter patent application to extend brilaroxazine exclusivity through 2046 [news · published 2026-08-12].
Sources: News · SEC filings · SEC MD&A · Generated October 4, 2026 · How we verify sources →
Run REVIVA PHARMACEUTICALS HOLDINGS, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available REVIVA PHARMACEUTICALS HOLDINGS, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
35
Total value held
$1.9M
| Holder | Shares | Value |
|---|---|---|
| millennium management llc | 793,948 | $579K |
| highbridge capital management llc | 762,236 | $556K |
| armistice capital, llc | 592,079 | $432K |
| vanguard capital management llc | 117,568 | $86K |
| warberg asset management llc | 90,772 | $66K |
| geode capital management, llc | 72,992 | $53K |
| renaissance technologies llc | 43,002 | $31K |
| vanguard fiduciary trust co | 31,598 | $23K |
| state street corp | 19,160 | $14K |
| blackrock, inc. | 18,582 | $14K |
Showing top 10 of 35 institutional holders of REVIVA PHARMACEUTICALS HOLDINGS, INC.. Open the full 13F history after sign-in.
Short Interest
as of Apr 28, 2026- % of float
- 11.5%
- Days to cover
- 1.3
- Shares short
- 1,429,477
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
RVPH short interestGovernance
Frequently asked questions
What is the AI investment thesis for REVIVA PHARMACEUTICALS HOLDINGS, INC.?
Reviva Pharmaceuticals Holdings, Inc. (RVPH) is a late-stage biopharmaceutical company focused on developing brilaroxazine for schizophrenia and other CNS disorders, with no approved products and a single advanced clinical candidate.
Who is the CEO of REVIVA PHARMACEUTICALS HOLDINGS, INC.?
Dr. Laxminarayan Bhat Ph.D. is the chief executive officer of REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH).
Where is REVIVA PHARMACEUTICALS HOLDINGS, INC. headquartered?
REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) is headquartered in Cupertino, CA, United States.
What therapeutic areas does REVIVA PHARMACEUTICALS HOLDINGS, INC. focus on?
REVIVA PHARMACEUTICALS HOLDINGS, INC. develops therapies across Neurology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.